Search hospitals > Michigan > Grand Rapids
START Midwest
Claim this profileGrand Rapids, Michigan 49546
Global Leader in Solid Tumors
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Colorectal Cancer
Conducts research for Pancreatic Cancer
113 reported clinical trials
6 medical researchers
Summary
START Midwest is a medical facility located in Grand Rapids, Michigan. This center is recognized for care of Solid Tumors, Lung Cancer, Cancer, Colorectal Cancer, Pancreatic Cancer and other specialties. START Midwest is involved with conducting 113 clinical trials across 192 conditions. There are 6 research doctors associated with this hospital, such as Nehal Lakhani, MD, Manish Sharma, MD, Katie Robinson, MD, and Sreenivasa Chandana, M.D., Ph.D..Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
KRAS positive
2Lung Cancer
Global LeaderStage IV
Stage III
KRAS positive
Top PIs
Nehal Lakhani, MDSTART Midwest5 years of reported clinical research
Expert in Lung Cancer
Studies Solid Tumors
25 reported clinical trials
30 drugs studied
Manish Sharma, MDSTART Midwest6 years of reported clinical research
Expert in Lung Cancer
Expert in Solid Tumors
19 reported clinical trials
30 drugs studied
Katie Robinson, MDSouth Texas Accelerated Research Therapeutics Midwest6 years of reported clinical research
Studies Lung Cancer
Studies Breast Cancer
6 reported clinical trials
9 drugs studied
Sreenivasa Chandana, M.D., Ph.D.START Midwest6 years of reported clinical research
Studies Colorectal Cancer
Studies Biliary Tract Cancer
6 reported clinical trials
21 drugs studied
Clinical Trials running at START Midwest
Lung Cancer
Breast Cancer
Solid Tumors
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Cancer
Endometrial Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
AU-007
for Advanced Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.
Recruiting1 award Phase 1 & 28 criteria
PRO1184
for Cancer
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Recruiting1 award Phase 1 & 27 criteria
BDTX-4933
for Cancer
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC with KRAS and/or BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.
Recruiting1 award Phase 1 & 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at START Midwest?
START Midwest is a medical facility located in Grand Rapids, Michigan. This center is recognized for care of Solid Tumors, Lung Cancer, Cancer, Colorectal Cancer, Pancreatic Cancer and other specialties. START Midwest is involved with conducting 113 clinical trials across 192 conditions. There are 6 research doctors associated with this hospital, such as Nehal Lakhani, MD, Manish Sharma, MD, Katie Robinson, MD, and Sreenivasa Chandana, M.D., Ph.D..
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.